ORIGINAL ARTICLE

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis

M Gärtner,1 I K Sigmund,1 F Alasti,1 G Supp,1 H Radner,1 K Machold,1 J S Smolen,1,2 D Aletaha1

ABSTRACT

Objectives: Clinical joint activity is a strong predictor of joint damage in rheumatoid arthritis (RA), but progression of damage might increase despite clinical inactivity of the respective joint (silent progression). The aim of this study was to evaluate the prevalence of silent joint progression, particularly on the patient level and to investigate the duration of clinical inactivity as a marker for non-progression on the joint level.

Methods: 279 patients with RA with any radiographic progression over an observational period of 3–5 years were included. We obtained radiographic and clinical data of 22 hand/finger joints over a period of at least 3 years. Prevalence of silent progression and associations of clinical joint activity and radiographic progression were evaluated.

Results: 120 (43.0%) of the patients showed radiographic progression in at least one of their joints without any signs of clinical activity in that respective joint. In only 7 (5.8%) patients, such silent joint progression would go undetected, as the remainder had other joints with clinical activity, either with (n=84; 70.0%) or without (n=29; 24.2%) accompanying radiographic progression. Also, the risk of silent progression decreases with duration of clinical activity.

Conclusions: Silent progression of a joint without accompanying apparent clinical activity in any other joint of a patient was very rare, and would therefore be most likely detected by the assessment of the patient. Thus, full clinical remission is an excellent marker of structural stability in patients with RA, and the maintenance of this state reduces the risk of progression even further.

INTRODUCTION

The links between synovial inflammation, joint damage and impairment of physical function are well established in rheumatoid arthritis (RA).1–6 Therefore, joint assessment is a central part of the evaluation of RA disease activity and it was consistently shown that radiographic progression in RA relates to clinical joint activity, especially joint swelling.7 8 This is a major reason why most common composite disease activity indices for RA employ swollen joint counts (SJC).9 10 Appropriate interference with disease activity according to such scores, therefore, has become the mainstay of RA management and will reduce or halt progression of damage and optimise physical function.11

However, joint progression despite clinical inactivity (‘silent’ progression) has been discussed as a potential risk for patients, as it may go clinically undetected and therefore may not lead to respective treatment adaptations. In particular, a low sensitivity of clinical joint assessment was proposed as a potential explanation for silent progression.12 One possible way to account for this critique would be to use more sensitive methods for detection of residual joint activity, such as ultrasound or MRI. The other possibility, however, is that silent progression in clinically inactive joints is detectable in patients who...
have significant activity in other joints, since the proinflammatory cytokines released from these joints are known to exert local and systemic osteoclastogenic effects, and thus could induce continuation of some joint damage via such systemic effects, especially in patients in whom osteoclasts are already active and have led to damage. The first part of our study explores how frequently this clinical situation is present.

In the second part of our study, we will investigate the association of disease activity and progression on the level of the individual joint. The existing literature on this topic has been partly inconsistent, because some associations were performed on the patient level only, and because the temporal gap between active disease (disease process) and manifestation of joint damage (disease outcome) is neglected in cross-sectional analysis. Thus, we will adopt a joint level analysis with consideration of joint activity longitudinally over several years to address this topic.

**METHODS**

### Database and patient selection

The basis of our analysis was a clinical practice data set of patients with a confirmed diagnosis of RA (based on the evaluation of the respective classification criteria at the time) who were 18 years or older. All routinely performed clinical, functional and radiographic assessments were documented for all visits since 1998. All therapies were initiated and adapted according to the clinical needs at the discretion of the treating rheumatologist and were also documented in the database. All data were accrued before the study was designed and none of the evaluators of joint activity or radiographs were aware of the questions raised in this study.

We selected only patients in whom at least one joint of the hands (wrist, metacarpophalangeal joints (MCP) or proximal interphalangeal joints (PIP)) had radiographic progression (increase ≥21) on the Sharp van der Heijde score (SHS) over an observation period of 3–5 years. This was done to exclude the non-progressing patients, who would not be informative for our study. Importantly, the ‘baseline X-ray’ in our study was not necessary the first X-ray taken from the patient as we also included clinical data 1 year prior to the first X-ray. No further restrictions, such as by treatment, disease duration, laboratory results or comorbidities, were applied. We considered radiographic progression in the 22 hand and finger joints (PIPs, MCPs and wrists), for which matching clinical joint assessment was available retrospectively.

Clinical data on individual joints (swelling and tenderness), as well as disease activity data and laboratory results on the patient level, were extracted from the patients’ charts for each clinical visit performed between 1 year prior to the baseline radiograph of this study until the time of the X-ray end point. Typically, these clinical data are documented every 3 months.

All eligible patients had at least one radiographic follow-up over a period of 3–5 years with a minimum of 10 clinical visits after the baseline assessment to ensure that the clinical data were representative of the observation period. The period of at least 3 years of radiographic observation was introduced to allow for a higher sensitivity for progression, and a greater specificity for non-progression. If a patient had more than one X-ray performed between years three and five from the index (baseline) radiograph, the earliest one was chosen for reasons of best data consistency.

### Clinical assessments

Patient demographics, such as age, gender and disease duration, as well as treatment type and status, were collected from the patients’ charts. Clinical tender and SJC scores were performed using a 28 joint count (shoulders, elbows, wrists, metacarpophalangeal joints, interphalangeal joints of the thumb, PIP, and knees); (TJC and SJC, respectively). Joint assessment was performed by two trained biometicians with good inter-observer reliability (ICC 0.8; 95% CI 0.77 to 0.83), in accordance with the recommendations by EULAR, classifying a joint as swollen and/or tender only if this was beyond doubt.

For the evaluation of pain, patient global assessment (PGA) and physician (evaluator) global assessment (EGA) of disease activity, visual analogue scales were used. To assess physical function, the Health Assessment Questionnaire Disability Index (HAQ) was performed at every outpatient visit. Additionally, laboratory results (including C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as well as rheumatoid factor (RF) and anticitrullinated peptide antibodies (ACPA) had been collected at every routine visit. Rheumatoid factor was routinely determined using nephelometry. For ACPA testing, IgG antibodies against cyclic citrullinated peptides (CCP2 test, second-generation assay) were measured on an ImmunoCAP250 using the EliA-CCP assay. These tests did not change during the observational period.

Disease activity was evaluated using the simplified and clinical disease activity index (SDAI, CDAI) and the disease activity score based on 28 joint counts, 4 variables and ESR (DAS28).

### Radiographic assessments

All radiographs were scored according to the SHS over clinical and disease activity index (SDAI, CDAI) and the disease activity score based on 28 joint counts, 4 variables and ESR (DAS28).

Radiographic assessments

All radiographs were scored according to the SHS by a trained reader (GS), unblinded for sequence but blinded to clinical assessment. Joints were scored for erosions (grade 0–5 per evaluated joint; 0=no erosion, 5=complete collapse of the joint or the total surface of the joint being affected) and joint space narrowing (JSN; grade 0–4; 0=normal joint space, 4=bony ankylosis or complete luxation of the joint). Thus, on the individual joint level, the SHS can amount up to 20, while the maximum SHS in the hands of a patient can be 280 (160 for erosion and 120 for JSN score). Progression at
the joint level was defined as a minimum increase of 1 (either in the erosion score or in the joint space narrowing score). Since the small joints of the wrists (the carpometacarpal joints, the radiocarpal joint, the scaphocarpal joint, the radioulnar joint as well as the os lunatum, os scaphoideum and os trapezium) are scored separately in the SHS, we summarised them and defined a minimum increase of 1 (either in erosion or in joint space narrowing) in any of these joints as radiographic progression of the wrist region. Intrarelerability on the SHS was high with an ICC of 94% in a subset of 41 images that were read twice; inter-reader reliability was also high with an ICC of 98% in a subset of 28 patients that were scored by two readers (GS and KK).

**Statistical analyses**

We first descriptively investigated the frequency of joints without clinical activity but with radiographic progression. Hereby, we addressed the first question of our study: does silent progression exist, and can clinical monitoring of all 28 joints be used to prevent it?

We then compared patients with radiographic progression only in joints with present or past clinical activity to patients with radiographic progression and no current or past clinical activity in the respective joint(s). The latter patients could of course also have one or more other clinically active joints, with or without radiographic progression. Differences between these groups in clinical variables, such as levels of CDAI, SDAI, DAS28, PGA, EGA or CRP, or treatment status were investigated.

In a subanalysis, we evaluated joints without radiographic damage at baseline for their radiographic progression.

Finally, we investigated the association between proportional duration of clinical activity (ie, time with documented swelling or tenderness divided by whole observation time, including activity 1 year prior to the baseline X-ray) and radiographic progression. We therefore used logistic regression analysis employing—in separate univariate models—either per cent of time clinically swollen, tender or both as independent variables, while in all models any progression in SHS in the respective joint (ie, change of ≤0 vs >0) was used as the dependent variable.

For statistical analyses, we used IBM SPSS software (V.20.0). T-Tests were performed for continuous data; analyses of variance were conducted for multiple group comparisons; and Pearson’s χ² tests were used to analyse categoric variables. Except for the initial descriptive assessment (see above), all analyses were primarily performed on the individual joint level.

The study was approved by the local ethics committee (ethics committee of the Medical University of Vienna) and conducted according to the guidelines of the Declaration of Helsinki. All patients on our register gave written consent to use their data from the database.

**RESULTS**

A total number of 279 patients (81.4% female) with a mean±SD number of 16.5±4.8 visits fulfilled the inclusion criteria for this study. Their baseline demographic and disease characteristics are shown in table 1. The mean observation period amounted to 4.1±0.7 years with a mean progression in total SHS of 5.8±15.4 (3.0±6.8 for JSN and 2.7±9.7 for erosion). During the observation period, the mean±SD radiographic progression per joint (non-progressing joints included) was 0.3±1.4, 0.1±0.8 for erosiveness and 0.2±0.8 for narrowing. Among the progressing joints (n=945), the mean progression per joint progressing radiologically (non-progressing joints excluded) was 1.9±2.0 (out of a total maximum score of 9), 1.8±1.3 for single joint erosion score (out of maximally 5), and 1.5±1.2 for single joint narrowing score (out of maximally 4). These data indicate that only relatively few individual joints had progression of both erosions and JSN (see below).

**What is the extent of progression when patients are regularly monitored aiming at remission?**

Figure 1 depicts a flow chart of the basic results among the 279 evaluated patients with radiographic progression; 159 (57.0%) of them showed progression only in joints that were clinically active (swollen and/or tender) at least once during the observation period. Of the 199 structurally progressing patients with active joints during the overall observation period, 63 (39.6%) showed changes in the overall joint space narrowing score, 22 (13.9%) changes in the overall joint erosion score and 74 (46.5%) progression in both. In these patients with radiographic progression, the mean number of joints with radiographic progression was 3.0±2.4. This number was similar for the joints that were only swollen (3.0±2.2) and those only tender during the observation period (3.0±2.4). In 132 of the 159 patients, clinical activity was seen only in the year before the baseline radiographic assessment, but not after this first radiograph was taken.

| Table 1 Baseline characteristics of all 279 included patients |
|-----------------------------|-------------------|
| **Total number of patients** | 279               |
| **Age mean (±SD), years**    | 60.2±12.1         |
| **Disease duration mean (±SD), years** | 12.7±9.1          |
| **RF positive n (%)**        | 167 (59.9%)       |
| **anti-CCP Ab, positive n (%)** | 194 (69.5%)      |
| **Mean (±SD) baseline CRP, mg/dL** | 0.85±1.43       |
| **(upper normal limit: <0.5)** |                   |
| **Mean (±SD) baseline HAQ**  | 0.79±0.75         |
| **Mean (±SD) baseline CDAI** | 9.0±9.6           |
| **Mean (±SD) baseline SDAI** | 9.8±9.5           |
| **Mean (±SD) SHS**           | 48.4±63.3         |

anti-CCP Ab, anticitrullinated peptide antibodies; CDAI, clinical disease activity index; CRP, C reactive protein; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SDAI, simplified disease activity index; SHS, van der Heijde-Sharp-Score.
Of the 279 patients, 120 (43.0%) exhibited one or more joints with radiographic progression despite clinical inactivity in that joint (absence of swelling and tenderness during the whole observation period including 1 year prior to the baseline X-ray), with progression of erosions seen in 22 (18.3%), progression of JSN in 59 (49.2%) and progression of both in 39 (32.5%). For the 120 patients without any clinical activity in the progressing joints, the mean number of joints with radiographic progression was 2.0±1.4.

Among these 120 patients (figure 1), 84 (70%) had at least one other joint in which progression of damage occurred in the presence of swelling or tenderness (like in the 159 patients described above), possibly suggesting that the events ongoing in these joints may have influenced damage in the apparently clinically unaffected joint.

Twenty-nine of these 120 patients (24.2%) showed clinically detectable disease activity in at least one other joint, although that joint did not progress. Together with the 84 patients just mentioned above, this eventually leaves only 7/120 patients (5.8%), who had a joint with progression of structural damage without any appreciable clinical activity as indicator for a progression (figure 1). Focusing on clinical swelling only, we found a similarly small proportion of patients showing progression in joints without clinical swelling and without any other swollen joint during the observational period (11/173; 6.4%).

**Differences between patients having structurally progressing joints with or without clinical joint activity**

Patients with radiographic progression in individual joints without apparent clinical disease activity (n=120; figure 1) had significantly lower levels of HAQ, PGA, EGA, pain scores, CDAI, SDAI and DAS28 compared to patients with progression in clinically active joints (table 2; p<0.01 for all). Interestingly, in patients with radiographic progression, despite clinical inactivity, HAQ values improved during the observation period (mean ±SD HAQ change −0.09±0.70, while physical function deteriorated in those being clinically active (HAQ progression+0.12±0.76; p<0.001).

Baseline SHS, on the other hand, was significantly higher in patients who had clinically inactive progressing joints compared to patients with clinically active progressing joints (59.7±73.4 vs 40.1±53.4; p<0.015). Importantly, in those seven patients with radiographic progression without any clinical activity baseline, SHS was even higher with a mean±SD of 146.5±194.4 and at least three
of them had high ACPA levels (mean±SD ACPA level of 213.9±282.8 U/mL).

**Influence of various treatment regimes**

The majority of the patients received conventional synthetic (cs) disease modifying antirheumatic drugs (DMARDs) for over 50% of the observation period, while 24.0% of the patients were treated with biological agents for more than 50% of that time. There was no significant difference in frequency of radiographic progression in clinically active/inactive joints comparing patients treated with a biological agent for more or less than 50% of the observation period (p=0.69 and p=0.19, respectively). We refrained from statistical modelling of treatment effects, as the composition of treatment segments was highly heterogeneous and variable in duration, and there is an established lag time between treatment effects, as the composition of treatment segments was highly heterogeneous and variable in duration, and there is an established lag time between treatment effect and structural progression.14

**Association of clinical joint activity (swelling and tenderness) with progression on the joint level**

When assessing all 6138 joints of the 279 patients with progression of SHS, we found this progression to be confined to 943 (15.4%) of these joints. Of these, 267 joints (28.3%) progressed in their erosion score, 533 (56.5%) in their narrowing score and 143 (15.2%) in both (figures 2 and 3). Of all joints with progression in erosions, 44 were swollen (16.5%; in 29 patients) and 34 were tender (12.7%; in 28 patients) at least once and 121 joints (45%; in 76 patients) were swollen and tender during the observation period (figure 2). Interestingly, 57 joints (6.2%; in 40 patients), which showed progression, were clinically active only during the year prior to the first X-ray, but not within the observation period, indicating a potential carry-over effect of past disease activity (or continuing subclinical disease activity) until damage manifested, as previously described.14 38 (0.6%) joints had undergone joint replacement surgery and were thus not included for further analysis. Figure 2 depicts the distribution of swelling and tenderness in joints with radiographic progression as well as the percentage of time of clinical joint activity.

Among the mentioned 6138 evaluated joints, 5157 (84.0%) showed no progression of joint damage during the observation period; among these, 2896 (56.2%) joints were clinically active during that time: 648 (12.7%) were only swollen and 838 (16.2%) were only tender, with 1410 (27.3%) exhibiting swelling and tenderness. The mean percentage of time with clinical activity (i.e., swelling or tenderness or both) was significantly shorter in non-progressing joints compared with progressing joints (figure 2; p<0.0001). Further, we found a significantly shorter proportional period of clinical swelling in joints without X-ray progression versus those with progression (14.9±24.2% vs 21.8±27.4% of time swollen during the observation period; p<0.0001). When we evaluated the probability of progression in dependence of the duration of joint activity (percentage of the total time in clinical activity in the respective joint) using logistic regression analysis, we found a significant association (p<0.0001). Conversely, the longer the time in clinical inactivity, the lower the estimated probability for radiographic progression (p<0.0001; figure 3).

**Progression in joints without damage at baseline**

Of the 943 joints with radiographic progression, 520 (55.1%, in 212 patients) showed no X-ray damage at baseline; 375 (195 joints in 71 patients) developed erosions, 56.0% (291 joints in 88 patients) developed joint space narrowing and 6.5% (34 joints in 53 patients) developed both.

---

**Table 2** Differences in clinical variables at baseline in patients with radiographic progression in clinically active/inactive joints

|                          | Progression+clinically active | Progression+clinically inactive | p Value |
|--------------------------|-------------------------------|--------------------------------|---------|
| RF (U/L), mean (±SD)     | 159±303                       | 106±171                        | 0.51    |
| RF % positive            | 61.0%                         | 58.3%                          | 0.65    |
| Anti-CCP Ab., mean (±SD) | 177±210                       | 175±189                        | 0.48    |
| Anti-CCP Ab. % positive  | 65.4%                         | 75.0%                          | 0.08    |
| CRP (mg/dL), mean (±SD)  | 0.9±1.4                       | 0.8±1.5                        | 0.06    |
| ESR (mm/h), mean (±SD)   | 25.3±19.3                     | 26.6±22                        | 0.86    |
| HAQ, mean (±SD)          | 0.9±0.7                       | 0.6±0.7                        | 0.003   |
| PGA, mean (±SD)          | 33.1±23.4                     | 22.2±21.9                      | <0.0001 |
| EGA, mean (±SD)          | 15.7±15.1                     | 8.5±10.9                       | <0.0001 |
| VAS, mean (±SD)          | 32.1±22.8                     | 21.9±20.7                      | <0.0001 |
| CDAI, mean (±SD)         | 11.6±10.3                     | 5.5±6.6                        | <0.0001 |
| SDAI, mean (±SD)         | 12.5±10.4                     | 6.1±6.7                        | <0.0001 |
| DAS 28, mean (±SD)       | 3.7±1.3                       | 2.9±1.1                        | <0.0001 |
| SHS at baseline, mean (±SD) | 40.1±53.4                  | 59.7±73.4                      | 0.015   |

Anti-CCP Ab.; anti-CCP antibodies; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28, disease activity score 28; EGA, evaluators global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; PGA, patient global assessment; RF, Rheumatoid Factor; SDAI, simplified disease activity index; SHS, van der Heijde-Sharp-Score; VAS, pain on a visual analogue scale.
No significant differences in percentages of clinically active time, duration of symptoms or duration of biological treatment were found between the patients with new signs of radiographic damage and those with progression in joints already affected at baseline.

DISCUSSION
In this study, we evaluated the influence of clinical joint activity on radiographic progression at the joint level in 279 patients with RA. Previously performed studies mostly included patients from clinical trials, requiring strict treatment regimens, or early patients with RA; none of these studies had an observation period of 4 years or more and none accounted for potential carry-over effects by also assessing clinical activity during the year before the baseline radiographs, as we did in the present study.

In accordance with previous data, we found that the majority of the joints with radiographic progression showed clinical activity such as swelling, tenderness or both at least once during the observation period. Only 6.2% of these joints exhibited clinical activity solely prior to the first X-ray, implying progression due to a putative carry-over effect. Nevertheless, every fourth joint with radiographic progression never showed any signs of clinical activity, not even during the year before the baseline X-ray; taking this finding to the patient level, every second individual had at least one such clinically inactive but radiographically progressing joint. However, among these patients, 94.2% had clinically active joints at another location, indicating that on the patient level only very few patients with inactive but progressive joints had full clinical remission. This is well in line with findings that patients fulfilling stringent clinical remission criteria, such as the ACR-EULAR criteria, are very rarely afflicted with residual sonographic synovitis and have very good physical function. Further, it was shown that keeping a state of stringent clinical remission seems to be equivalent to sonographic remission considering radiographic progression.

Explanations for such damage progression despite clinical inactivity or progression of joint destruction in joints distant from the clinically active joints can only be speculative: (1) patients could have subclinical synovitis as shown by some sonographic studies, but also by the
fact that according to the EULAR handbook of standard methods doubtfully active joints are considered as not clinically active; on the other hand, sonographic data per se are often not unequivocal, in an experimental model, Lefèvre et al showed that activated synovial fibroblasts can move from an inflamed joint to a distant, unaffected joint and elicit damage, since fibroblasts can drive osteoclastogenesis; autoantibodies, in particular anti-CCP antibodies, may activate osteoclasts directly and thus active synovitis may not always be needed; pre-existing joint damage may enhance joint destruction either by pure mechanical forces or secondary to microenvironmental mechanisms; and proinflammatory cytokines released from active joints can act systemically as evidenced by axial osteoporosis in experimental models and patients with active RA, and therefore the presence of significant joint activity might affect damage in distant, clinically quiescent joints, if the damage process has been ignited; indeed, the fact that patients with progression in clinically inactive joints exhibit more damage at baseline supports this possibility.

There are several limitations to our study. First, this study comes from a single centre and confirmatory data from other centres will be needed; however, even in clinical trials with short periods of follow-up, joint damage progression was associated primarily with clinical activity, but some clinically inactive joints also exhibited radiographic progression. Second, we focused only on joints of the hands, while the feet are also evaluated by the radiographic scores; however, this allowed assessment of pertinent relationships between clinical and radiographic activity, since the routinely performed 28 joint count does not comprise the feet; moreover, clinical assessment of the feet may be obscured by problems which are not related to RA. Importantly, however, we are not aware that hands and feet behave differently in terms of progression of joint damage, even though they may behave differently in terms of detectable clinical activity, a discrepancy which in fact has led to the development of the 28 joint count. Third, while data in figure 1 are presented on the patient level, analysis depicted in figure 2 and the models for figure 3 were based on the joint level, and were therefore not independent (multiple joints per patient). Fourth, owing to the various mixed treatment segments over the 3–5-year study period and the lag times associated with structural treatment effects, we refrained from complex modelling of various therapies or using longitudinal data analysis (including multiple X-rays). As a guidance on the magnitude of the effect of therapies, we performed descriptive analyses using duration of the various treatment segments, particularly of biological compounds. Further, interobserver reliability of joint examination is generally low; however, assessments at our clinics are routinely performed by a specifically dedicated team of biometricians to ensure longitudinal reliability. Finally, the data obtained here may not be generalisable to all RA populations, since there can be differences in risk and extent of progression.

Importantly, the time spent with a clinically active joint was significantly predicting progression of structural damage in the respective joint. This association was best for the “overall” activity (swelling and/or tenderness), followed by swelling and tenderness. All these observations support current paradigms and recommendations of achieving full clinical remission (ie, absence of clinical joint activity) in patients with RA, since, on the basis of our findings, this would also warrant the absence of progression in any other joint in most patients.

As expected, patients with progressing joints without clinical activity in these joints showed lower overall disease activity than patients with progressing joints that were clinically active. Interestingly, however, they had significantly higher baseline radiographic scores, further supporting some of the above potential explanations for our findings, as well as the well-established concept that patients with erosive disease are the most likely ones to develop new erosions. Our data suggest that this risk even overrules the risk of progression affiliated with (ongoing) disease activity. Further, it has to be mentioned that patients with progression in clinically inactive joints even improved in HAQ values over time, thus suggesting only a small impact of radiographic progression on physical function in these patients.

CONCLUSION

While damage may progress in some joints despite lack of any clinical activity in these joints, this event is heralded by the presence of significant pre-existing joint damage and occurs very rarely in patients whose disease activity is in full clinical remission. These observations

Figure 3

Estimated Probability of Progression (% of total observational time) and radiographic progression. It is shown that the longer the joint was not swollen (blue line), not tender (red line) or not swollen and not tender (green line), the lower was the probability of radiographic progression (p<0.0001 for all).
strongly support the importance of using composite measures that include formal clinical joint examinations with the objective of achieving a state of full clinical remission.

Acknowledgements The authors thank Kerstin Klöckl (KK) for supporting the X-ray reading.

Contributors MG carried out data acquisition, analysis, study conception and the writing of the manuscript; IKS carried out data acquisition and drafted the manuscript; FA carried out data analysis and the manuscript revision; GS read all X-rays and revised the manuscript; HR carried out data acquisition and drafted the manuscript; KM and JS carried out the conception and design and manuscript revision. DA carried out the conception and design and data interpretation and manuscript revision. All authors read and approved the final manuscript.

Funding This work was supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115142 (BTCure) and by funding from the European Community’s Seventh Framework Programme (project EuroTEAM; Projectnumber: 305349).

Competing interests None declared.

Ethics approval Ethics committee of the Medical University of Vienna.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Drossaers-Bakker KW, de Buck M, van Zeiben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854–60.

2. Landwe R, van der Heijde D, Klareskog L, et al. Disconnection between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119–29.

3. Odegard S, Landwe R, van der Heijde D, et al. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006;54:68–75.

4. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020–30.

5. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823–7.

6. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.

7. Aletaha D, Boa F, Smolen JS. Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. Ann Rheum Dis 2011;70:1975–80.

8. Navarro-Compan V, Gherhe AM, Smolen JS, et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology (Oxford) 2015;54:994–1007.

9. [No authors listed]. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:713–22.

10. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2008;32:9–44, vii.

11. Smolen JS, Aletaha D, Bijlstra JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

12. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2005;53:2958–67.

13. Sabokbar A, Mahoney DJ, Hemingway F, et al. Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases. Clin Rev Allergy Immunol 2015 [Epub ahead of print 17 Nov 2015].

14. Aletaha D, Funovits PC, van der Heijde DM, et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60:1242–9.

15. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission, according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702–11.

16. Molenaar ET, Voskyei AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36–42.

17. van der Heijde D, Breedveld FC, Kavanyaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate. 5-year results of PREMIER. J Rheumatol 2010;37:2327–40.

18. van der Heijde D. Remission by imaging in rheumatoid arthritis: should this be the ultimate goal? Ann Rheum Dis 2012;71(Suppl 2):i89–92.

19. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.

20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

21. Studenic P, Radner H, Smolen JS, et al. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64:2814–23.

22. van der Heijde D. How to read radiographs: an update of the Sharp/ van der Heijde method. J Rheumatol 1999;26:743–5.

23. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification). J Rheumatol 1995;22:1792–6.

24. Smolen JS, Breedveld FC, Eber G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38–43.

25. Scott D, Van Riel PL, van der Heijde DM, et al. Assessing disease activity in rheumatoid arthritis—The EULAR handbook of standard methods. On behalf of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials—EUCISIT (Chairman: Smolen JS). EULAR, Zürich 1999.

26. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.

27. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.

28. Aletaha D, Neil VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.

29. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:683–75.

30. Kinwan J, Byron M, Watt I. The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:297–301.

31. Kinwan JR. The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1997;36:225–8.

32. Klarenbeek NB, Guler-Yuksel M, van der Heijde DM, et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in
patients initially treated with infliximab. *Ann Rheum Dis* 2010;69:2107–13.

33. Luukkainen R, Kaarela K, Isomaki H, et al. Relationship between clinical synovitis and radiological destruction, in rheumatoid arthritis. *Clin Rheumatol* 1983;2:223–6.

34. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. *Ann Rheum Dis* 1988;47:648–53.

35. Balsa A, de Miguel E, et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. *Rheumatology (Oxford)* 2010;49:683–90.

36. Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. *Arthritis Rheum* 2013;68:2056–14.

37. Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. *Ann Rheum Dis* 2013;72:245–9.

38. Haavardsholm EA, Aga AB, Olsen IC, et al. Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen. *ACR*. 2015.

39. Kawashiri SY, Suzuki T, Nakashima Y, et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. *Rheumatology (Oxford)* 2013;53:562–9.

40. Jousse-Joulin S, D’Agostino MA, Marhadour T, et al. Reproducibility of joint swelling assessment by sonography in patients with long-lasting rheumatoid arthritis (SEA-Repro study part II). *J Rheumatol* 2010;37:938–45.

41. Koski JM, Saarakkala S, Helle M, et al. Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments. *Ann Rheum Dis* 2006;65:1590–5.

42. Marhadour T, Jousse-Joulin S, Chales G, et al. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). *J Rheumatol* 2010 May;37:932–7.

43. Lefevere S, Kredia A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. *Nat Med* 2009;15:1414–20.

44. Koreny T, Tunyogi-Csapo M, Gal I, et al. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. *Arthritis Rheum* 2006;54:3221–32.

45. Hame U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. *J Clin Invest* 2012;122:1791–802.

46. Messner K, Fahlgren A, Persliden J, et al. Radiographic joint space narrowing and histologic changes in a rabbit meniscectomy model of early knee osteoarthritis. *Am J Sports Med* 2001;29:151–60.

47. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. *Nat Rev Drug Discov* 2012;11:234–50.

48. Grunke M, Witt MN, Ronneberger M, et al. Use of the 28-joint count yields significantly higher concordance between different examiners than the 66/68-joint count. *J Rheumatol* 2012;39:1334–40.

49. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014;73:492–509.

50. Tobon G, Saura A, Lukas G, et al. First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. *Arthritis Care Res (Hoboken)* 2013;65:1907–15.